People · Operator
Named in public records as an officer, director or promoter · active 2008–2011 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| LigoCyte Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $50.1M | $68.0M | 2008 |
| Artisan Pharma, Inc. | — | Biotechnology | Series B | $50.0M | $119.1M | 2009 |
| Singulex Inc | — | Biotechnology | Series B | $44.7M | $483.8M | 2011 |
| Kythera Biopharmaceuticals Inc | — | Pharmaceuticals | Series B | $37.4M | $1.3B | 2011 |
Hironori Hozoji at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Hironori Hozoji on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Robert Nelsen | 1 | 22 |
| Ben Auspitz | 1 | 9 |
| Gregory Johnson | 1 | 8 |
| David Schnell | 1 | 7 |
| Ivor Royston | 1 | 7 |
| CARL L. GORDON | 1 | 7 |
| Camille Samuels | 1 | 6 |
| Heiner Dreismann | 1 | 6 |
| Georg Nebgen | 1 | 5 |
| Dennis Fenton | 1 | 4 |
| Joseph Turner | 1 | 4 |
| C. Boyd Clarke | 1 | 4 |
| Thong-Yuen Poon | 1 | 3 |
| Robert Goodwin | 1 | 3 |
| Francois Kress | 1 | 3 |
| Nathaniel David | 1 | 3 |
| Gregory R. Johnson | 1 | 3 |
| Stephen Rose | 1 | 3 |
| Jeffrey D. Wager | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.